Business

ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

PRINCETON, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will

Ani Pharmaceuticals, Inc.February 18, 20254
ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2024 Financial Results on February 28, 2025, at 8:00 a.m. ET

About this update from Ani Pharmaceuticals, Inc.

PRINCETON, N.J. , Feb. 18, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (NASDAQ: ANIP) today announced that the Company will release its fourth quarter and full year 2024 financial results on Friday, February 28, 2025 , prior to the market open. Nikhil Lalwani , President and Chief Executive Officer, Stephen P. Carey , Senior Vice President, Finance, and Chief Financial Officer, and Chris Mutz , Head of Rare Disease, will host a conference call to discuss the results as follows: Date Friday, February 28, 2025 Time 8:00 a.m. ET Toll free ( U.S. ) 800-579-2543 Conference ID 4860276 Webcast (live and replay) www.anipharmaceuticals.com , under the “Investors” section A replay of the conference call will be available within two hours of the call’s completion and will remain accessible for two weeks by dialing 800-756-0554 and entering access code 4860276. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its mission of “Serving Patients, Improving Lives" by developing, manufacturing, and commercializing innovative and high-quality therapeutics. The Company is focused on delivering sustainable growth through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; its Generics business, which leverages R&D expertise, operational excellence, and U.S. -based manufacturing; and its Established Brands business. For more information, visit www.anipharmaceuticals.com . Investor Relations Contact: Lisa M. Wilson , In-Site Communications, Inc. 212-452-2793 [email protected] SOURCE: ANI Pharmaceuticals, Inc. Source: ANI Pharmaceuticals, Inc.

View stock analysis, news, and events for Ani Pharmaceuticals, Inc.

More from Ani Pharmaceuticals, Inc.

All Ani Pharmaceuticals, Inc. news →